| 0006-0461 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Physicians Total Care, Inc. |
| 0006-0461 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0461-01 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0461-02 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0461-06 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0461-12 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0462 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0462-01 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0462-06 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0464 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Rebel Distributors Corp |
| 0006-0464 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0464-01 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0464-05 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-0464-10 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-3061 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme LLC |
| 0006-3061 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND ® (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme LLC |
| 0006-3061-00 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND ® (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme LLC |
| 0006-3061-00 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme LLC |
| 0006-3061-01 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme LLC |
| 0006-3061-01 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND ® (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme LLC |
| 0006-3066 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-3066-01 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-3066-03 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-3862 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-3862 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Physicians Total Care, Inc. |
| 0006-3862-03 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-3862-13 | These highlights do not include all the information needed to use EMEND CAPSULES and EMEND FOR ORAL SUSPENSION safely and effectively. See full prescribing information for EMEND CAPSULES and EMEND FOR ORAL SUSPENSION. EMEND (aprepitant) capsules, for oral use EMEND (aprepitant) for oral suspension Initial U.S. Approval: 2003 | Merck Sharp & Dohme LLC |
| 0006-3884 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme Corp. |
| 0006-3884-01 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme Corp. |
| 0006-3884-32 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme Corp. |
| 0006-3941 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme Corp. |
| 0006-3941-01 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme Corp. |
| 0006-3941-32 | These highlights do not include all the information needed to use EMEND FOR INJECTION safely and effectively. See full prescribing information for EMEND FOR INJECTION. EMEND (fosaprepitant) for injection, for intravenous use Initial U.S. Approval: 2008 | Merck Sharp & Dohme Corp. |
| 0143-9384 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Hikma Pharmaceuticals USA Inc. | Qilu Pharmaceutical Co, Ltd. |
| 0143-9384-01 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Hikma Pharmaceuticals USA Inc. | Qilu Pharmaceutical Co, Ltd. |
| 0143-9428 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Hikma Pharmaceuticals USA Inc. | Qilu Pharmaceutical Co, Ltd. |
| 0143-9428-01 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Hikma Pharmaceuticals USA Inc. | Qilu Pharmaceutical Co, Ltd. |
| 0338-0008 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for Injection, for intravenous use Initial U.S. Approval: 2008 | Baxter Healthcare Corporation |
| 0338-0008-01 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for Injection, for intravenous use Initial U.S. Approval: 2008 | Baxter Healthcare Corporation |
| 0591-4385 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Actavis Pharma, Inc. |
| 0591-4385-79 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Actavis Pharma, Inc. |
| 0781-2321 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-2321-06 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-2321-51 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-2322 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-2322-06 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-2322-46 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-2322-68 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-2323 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-2323-06 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-2323-68 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-4063 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 0781-4063-36 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval: 2003 | Sandoz Inc |
| 13668-591 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-591-80 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-591-81 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-591-82 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-592 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-592-83 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-592-84 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-592-85 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-592-86 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-593 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-593-80 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-593-86 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-594 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 13668-594-87 | These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Torrent Pharmaceuticals Limited | Torrent Pharma, Inc | Pharmathen International S. A. |
| 16714-248 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval. 2008 | NorthStar RxLLC | Aspiro Pharma Limited |
| 16714-248-01 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval. 2008 | NorthStar RxLLC | Aspiro Pharma Limited |
| 31722-165 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Camber Pharmaceuticals, Inc. | Aspiro Pharma Limited |
| 31722-165-31 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Camber Pharmaceuticals, Inc. | Aspiro Pharma Limited |
| 42254-160 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Rebel Distributors Corp |
| 42254-160-01 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Rebel Distributors Corp |
| 43598-671 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION . FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Dr. Reddy's Laboratories Inc., | Dr.Reddy's Laboratories Limited-FTO-9 |
| 43598-671-11 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION . FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Dr. Reddy's Laboratories Inc., | Dr.Reddy's Laboratories Limited-FTO-9 |
| 43598-859 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Dr. Reddy's Laboratories Inc., | MSN LABORATORIES PRIVATE LIMITED |
| 43598-859-11 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Dr. Reddy's Laboratories Inc., | MSN LABORATORIES PRIVATE LIMITED |
| 43598-948 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Dr. Reddy's Laboratories Inc., | MSN LABORATORIES PRIVATE LIMITED |
| 43598-948-11 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Dr. Reddy's Laboratories Inc., | MSN LABORATORIES PRIVATE LIMITED |
| 47426-201 | These highlights do not include all the information needed to use CINVANTI ® safely and effectively. See full prescribing information for CINVANTI. CINVANTI ® (aprepitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2003 | Heron Therapeutics, Inc. | Alcami Carolinas Corporation | Sharp Corporation | Curia New Mexico, LLC | Pharma Packaging Solutions | Glenmark Life Sciences, Ltd. | Eurofins BioPharma Product Testing Columbia, Inc. | SPS Pharma Services | Particle Technology Group LLC, dba Particle Technology Labs | SGS North America Inc. |
| 47426-201 | These highlights do not include all the information needed to use CINVANTI ® safely and effectively. See full prescribing information for CINVANTI. CINVANTI ® (aprepitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2003 | Heron Therapeutics, Inc. | Alcami Carolinas Corporation | Curia New Mexico, LLC | Pharma Packaging Solutions | Eurofins BioPharma Product Testing Columbia, Inc. | SPS Pharma Services | Particle Technology Group LLC, dba Particle Technology Labs | SGS North America Inc. | Alivus Life Sciences, Limited | MSN Pharmachem Private Limited |
| 47426-201-01 | These highlights do not include all the information needed to use CINVANTI ® safely and effectively. See full prescribing information for CINVANTI. CINVANTI ® (aprepitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2003 | Heron Therapeutics, Inc. | Alcami Carolinas Corporation | Curia New Mexico, LLC | Pharma Packaging Solutions | Eurofins BioPharma Product Testing Columbia, Inc. | SPS Pharma Services | Particle Technology Group LLC, dba Particle Technology Labs | SGS North America Inc. | Alivus Life Sciences, Limited | MSN Pharmachem Private Limited |
| 47426-201-01 | These highlights do not include all the information needed to use CINVANTI ® safely and effectively. See full prescribing information for CINVANTI. CINVANTI ® (aprepitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2003 | Heron Therapeutics, Inc. | Alcami Carolinas Corporation | Sharp Corporation | Curia New Mexico, LLC | Pharma Packaging Solutions | Glenmark Life Sciences, Ltd. | Eurofins BioPharma Product Testing Columbia, Inc. | SPS Pharma Services | Particle Technology Group LLC, dba Particle Technology Labs | SGS North America Inc. |
| 47426-401 | These highlights do not include all the information needed to use APONVIE ® safely and effectively. See full prescribing information for APONVIE. APONVIE ® (aprepitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2003 | Heron Therapeutics, Inc. | Alcami Carolinas Corporation | Integrated Commercialization Solutions, LLC | Alivus Life Sciences, Limited |
| 47426-401 | These highlights do not include all the information needed to use APONVIE ® safely and effectively. See full prescribing information for APONVIE. APONVIE ® (aprepitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2003 | Heron Therapeutics, Inc. | Alcami Carolinas Corporation | Integrated Commercialization Solutions, LLC |
| 47426-401-01 | These highlights do not include all the information needed to use APONVIE ® safely and effectively. See full prescribing information for APONVIE. APONVIE ® (aprepitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2003 | Heron Therapeutics, Inc. | Alcami Carolinas Corporation | Integrated Commercialization Solutions, LLC | Alivus Life Sciences, Limited |
| 47426-401-01 | These highlights do not include all the information needed to use APONVIE ® safely and effectively. See full prescribing information for APONVIE. APONVIE ® (aprepitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2003 | Heron Therapeutics, Inc. | Alcami Carolinas Corporation | Integrated Commercialization Solutions, LLC |
| 47426-401-10 | These highlights do not include all the information needed to use APONVIE ® safely and effectively. See full prescribing information for APONVIE. APONVIE ® (aprepitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2003 | Heron Therapeutics, Inc. | Alcami Carolinas Corporation | Integrated Commercialization Solutions, LLC |
| 47426-401-10 | These highlights do not include all the information needed to use APONVIE ® safely and effectively. See full prescribing information for APONVIE. APONVIE ® (aprepitant) injectable emulsion, for intravenous use Initial U.S. Approval: 2003 | Heron Therapeutics, Inc. | Alcami Carolinas Corporation | Integrated Commercialization Solutions, LLC | Alivus Life Sciences, Limited |
| 51407-701 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-701-01 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-701-05 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-701-11 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-702 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-702-02 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-702-06 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-702-11 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-702-22 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-703 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-703-06 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-703-66 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-704 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 51407-704-03 | APREPITANT CAPSULES. These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. APREPITANT capsules, for oral use Initial U.S. Approval:2003 | Golden State Medical Supply, Inc. | Pharmathen International S. A. |
| 54868-5231 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Physicians Total Care, Inc. |
| 54868-5231-1 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Physicians Total Care, Inc. |
| 54868-5231-2 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Physicians Total Care, Inc. |
| 54868-5231-3 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Physicians Total Care, Inc. |
| 54868-5325 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Physicians Total Care, Inc. |
| 54868-5325-0 | These highlights do not include all the information needed to use EMEND safely and effectively. See full prescribing information for EMEND. EMEND (aprepitant) Capsules Initial U.S. Approval: 2003 | Physicians Total Care, Inc. |
| 55150-299 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Eugia US LLC | EUGIA PHARMA SPECIALITIES LIMITED |
| 55150-299-01 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Eugia US LLC | EUGIA PHARMA SPECIALITIES LIMITED |
| 63323-972 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Fresenius Kabi USA, LLC |
| 63323-972-10 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Fresenius Kabi USA, LLC |
| 67184-0540 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical (Hainan) Co., Ltd. |
| 67184-0540-1 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical (Hainan) Co., Ltd. |
| 67457-889 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION . FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Mylan Institutional LLC |
| 67457-889-10 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION . FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | Mylan Institutional LLC |
| 68001-421 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | BluePoint Laboratories | Apotex Inc | Gland Pharma Limited |
| 68001-421-22 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | BluePoint Laboratories | Apotex Inc | Gland Pharma Limited |
| 68001-523 | These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION. FOSAPREPITANT for injection, for intravenous use Initial U.S. Approval: 2008 | BluePoint Laboratories | Aspiro Pharma Limited |